BREAKING NEWS Monash IVF CEO resigns after fertility giant admitted to two embryo bungles in as many months
The CEO of embattled Monash IVF has resigned after the fertility giant admitted to its second embryo bungle in as many months.
Monash IVF Group chief executive Michael Knaap stood down from the role he had held since 2019 on Thursday.
Monash IVF chief financial officer Malik Jainudeen has been appointed as acting CEO, the Australian Financial Review reported.
More to come.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
2 hours ago
- Daily Mail
Anthony Albanese yet to secure crunch meeting with Donald Trump as he jets off to meet other world leaders
Anthony Albanese is jetting off abroad to meet other world leaders, yet has been criticised for failing to secure an official meeting with Donald Trump as the US administration applies pressure on Australia's defence spending. The Prime Minister will leave Canberra on Friday to meet his 'dear friend', the Prime minister of Fiji, Sitiveni Rabuka, before then travelling on to Seattle for a meeting of world business leaders. His next stop will be the G7 summit in the mountainous Canadian town of Kananaskis where Albanese will cross paths with the US President, just days after the Pentagon announced it was launching a review into the $368bn AUKUS submarine deal. 'I look forward to working productively with world leaders to discuss how we tackle some of the most challenging issues facing Australia, our region, and the world,' Albanese said. But the Opposition has been critical of his inability to lock in a meeting with Trump, at time when the AUKUS deal hangs in the balance and Australia is facing punitive tariffs. It also comes at a time when the US President has put pressure on Australia to increase its defence spending to 3.5 per cent of GDP - up from the current rate of around 2.3 per cent. Albanese has spoken over the phone twice to President Trump since he was re-elected in November last year but the pair are yet to have a face-to-face meeting. Opposition Leader Sussan Ley said on Friday morning she was 'concerned' about the US review into the AUKUS deal by Defence Under Secretary for Policy, Elbridge Colby, who she claimed was a 'a sceptic of AUKUS'. Under the $368 billion submarine program, Australia is set to acquire at least three nuclear-powered Virginia-class boats from the US in the early 2030s before a new fleet is built for delivery from the 2040s. The pact between Australia, the US, and the UK is aimed at countering China's expanding presence in the Indo-Pacific. But the Pentagon review will assess whether the deal meets Trump's 'America First' objective. Ley acknowledged that it was 'really hard' to secure a meeting with the US President, but she insisted Albanese had to have a face-to-face meeting. 'Lots of other world leaders have had that meeting. We haven't,' Ley told KIIS FM. However, Trump is yet to lock in any meetings with other world leaders, The Australian reported. The G7 brings together seven of the world's largest advanced economies – Canada, France, Germany, Italy, Japan, the United Kingdom and the United States – and the European Union. Climate and security are expected to dominate the diplomatic talks between leaders. Australia is not a member of the G7, but Canadian prime minister Mark Carney extended an invitation to Albanese. He is expected to meet with the US president on the sidelines of the conference, where he could try to carve out a tariff exemption. Australia is facing 10 per cent tariffs on goods exported to the US and - like every US trading partner except the UK - has been hit with 50 per cent tariffs on aluminium and steel sent to America. The Australian government has called the trade measures an 'act of economic self-harm' and is considering using critical minerals and US beef imports as bargaining chips. Albanese has not yet confirmed whether he will meet with Trump, though other bilateral discussions have been organised with the leaders of Canada, the UK, South Korea and Japan.
Reuters
4 hours ago
- Reuters
New Zealand manufacturing contracts in May amid economic uncertainties
SYDNEY, June 13 (Reuters) - Manufacturing activity in New Zealand fell back into contraction in May, after four straight months of expansion, because of weak demand, rising costs and low business confidence amid global economic uncertainties, a survey showed on Friday. The Bank of New Zealand-Business NZ's seasonally adjusted Performance of Manufacturing Index (PMI) dipped to 47.5 from a revised 53.3 in April. New orders slumped to 45.3 from a revised 50.8 in the prior month. A reading above 50 indicates manufacturing activity is expanding, while anything below that threshold points to contraction. "The New Zealand economy can claw its way forward over the course of 2025, but the PMI is yet another indicator that suggests an increased risk that the bounce in GDP ... could come to a grinding halt," BNZ Senior Economist Doug Steel said.
Reuters
5 hours ago
- Reuters
US FDA puts on hold Rein Therapeutics' lung disease drug trial
June 12 (Reuters) - Rein Therapeutics (RNTX.O), opens new tab has paused patient enrollment and dosing in a mid-stage trial of its lung disease drug in the U.S. after the Food and Drug Administration placed a clinical hold, the drug developer said on Thursday. Shares of the company fell nearly 10% after the bell. The company was testing a drug named LTI-03 to treat patients with idiopathic pulmonary fibrosis (IPF). The disease causes scarring of the lungs that makes it harder for them to work properly. Rein said in a filing that it is actively working with the FDA to remove the clinical hold. The FDA and Rein did not immediately respond to Reuters' requests for comment on why the hold was placed. The drug was well-tolerated and safe in an early-stage study in patients with IPF, the company said in the filing. No drug-related serious adverse events have been reported in any studies treating patients with LTI-03, it added. Rein continues to study the drug and enroll patients in Australia and Europe.
